Telix Pharmaceuticals News and Activities

Telix Pharmaceuticals is one of the...

• S&P/ASX200.

Telix Pharmaceuticals is a company listed under the stock ticker TLX (AU).

Telix Pharmaceuticals has a direct presence in 3 countries.

Telix Pharmaceuticals has 3 subsidiaries including Telix Pharmaceuticals Americas, Telix Pharmaceuticals APAC and Telix Pharmaceuticals EMEA.

View the org chart displaying its 40 main executives

Most searched biographies at Telix Pharmaceuticals

• Christian Behrenbruch, Director, Group Managing Director and Chief...
• Mark Nelson, Non-Executive Director
• Jann Skinner, Non-Executive Director

Popular executive movements at Telix Pharmaceuticals

• Maria Rivas will join the company as Director on May 11, 2026  (posted on April 10 2026).
• William Jellison has joined the company as Director  (posted on April 10 2026).
• David Gill will join the company as Non-Executive Director on Jun. 11, 2026  (posted on April 2 2026).

Create your alert
to follow the executive moves at Telix Pharmaceuticals.

Telix Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Telix Pharmaceuticals

• Telix at ASCO 2026 | Telix Pharmaceuticals
• Telix at SNMMI 2026 | Telix Pharmaceuticals
• Wilex Signs Antibody License Agreement With Telix Pharmaceuticals Limited | Telix Pharmaceuticals
• Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences | Telix Pharmaceuticals
• IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing | Telix Pharmaceuticals
• Fighting for Every Day | Telix Pharmaceuticals
• Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | Telix Pharmaceuticals
• OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer | Telix Pharmaceuticals
• TLX101-Px (Pixlumi®) MAA Accepted in Europe | Telix Pharmaceuticals
• New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC | Telix Pharmaceuticals
• View more press releases Close

Social media about Telix Pharmaceuticals

• Telix Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Telix Pharmaceuticals on LinkedIn, X (Twitter) & YouTube